ESMO26: Combination therapies show promise in prostate cancer

Bayer’s Nubeqa is already well established in prostate cancer, but DASL-HiCaP data broadens potential patient populations. Bayer’s Nubeqa is already well established in prostate cancer, but DASL-HiCaP data broadens potential patient populations. Prostate cancer is difficult to treat as some tumours are slow growing while others are aggressive. Credit: Jo Panuwat D / Shutterstock.com Prostate cancer is the most diagnosed cancer in men worldwide, but little is known about why some cancers are slow-growing, with patients remaining symptom-free, and why some cancers become aggressive. This uncertainty complicates research and clinical decision-making. Standard screening tests cannot reliably tell the difference between…

Source: Clinical Trials Arena